ScholarIQanswers from OpenAlex & ORCID
David Ferry
ResearcherPublications, citations & collaboration network
David Ferry is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Ferry have?
ScholarIQindexed works
David Ferry has 155 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Ferry have?
ScholarIQcitation count
David Ferry has 16,541 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Ferry?
ScholarIQh-index
David Ferry has an h-index of 53 in OpenAlex.
What is the i10-index of David Ferry?
ScholarIQi10-index
David Ferry has an i10-index of 103 in OpenAlex.
What is the OpenAlex record for David Ferry?
ScholarIQopenalex
The OpenAlex for David Ferry is on the source record.
What are the most-cited papers on David Ferry?
ScholarIQmost cited works
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs, Jiří Tomášek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David Ferry, Bohuslav Melichar, Mustapha Tehfé, Э. Э. Топузов, John Zalcberg, Ian Chau, William Campbell, Choondal Devan Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M. Liepa, Ling Gao, Jonathan D. Schwartz, Josep Tabernero
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah‐Eddin Al‐Batran, Eric Van Cutsem, David H. Ilson, María Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter C. Enzinger, Vera Gorbounova, Zev A. Wainberg, Susanna Hegewisch‐Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A. Shah, Alexander Luft, Nina Karaseva, Rubén Dario Kowalyszyn, Carlos Alberto Hernández, Tibor Csőszi, Ferdinando De Vita, Per Pfeiffer, Naotoshi Sugimoto, Judit Kocsis, Andràs Csilla, G. Bodoky, Georgina Garnica Jaliffe, Светлана Проценко, Ayman Madi, Elżbieta Wójcik, Baruch Brenner, Gunnar Folprecht, Tomasz Sarosiek, Katriina Peltola, Peter Bono, Hubert Ayala, Giuseppe Aprile, Cardellino Giovanni Gerardo, Fidel David Huitzil Melendez, Alfredo Falcone, Francesco Di Costanzo, Moustapha Tehfe, Laurent Mineur, Pilar Alfonso, Radka Obermannová, Hélène Senellart, Russell Petty, Leslie Samuel, Péter Ács, Maen Hussein, M. Nechaeva, Frans Erdkamp, Elizabeth Won, Johanna C. Bendell, Javier Gállego, Sylvie Lorenzen, Bohuslav Melichar, Miguel Angel Escudero, Denis Pezet, Jean–Marc Phelip, Diego Kaen, James A. Reeves, Federico Longo Muñoz, Srinivasan Madhusudan, Carlo Barone, Luis Fein, Ángel Gómez Villanueva, Mohamed Hebbar, Jana Prausová, L. Visa Turmo, J. Vidal Barrull, Mette Yilmaz, Alex Beny, Hanneke W.M. van Laarhoven, Brian DiCarlo, Taito Esaki, Kazumasa Fujitani, Karen Geboes, Ravit Geva, Shigenori Kadowaki, Stephen Leong, Nozomu Machida, Moses S. Raj, Francisco Javier Ramírez Godinez, Ágnes Ruzsa, Hugo Ford, William Lawler, Nicolas Robert Maisey, Jiřı́ Petera, Einat Shacham‐Shmueli, Isabelle Sinapi
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila, Emiliano Calvo, Luis Paz‐Ares, Philippe A. Cassier, Johanna C. Bendell, Nicolas Penel, Matthew Krebs, Juan Martín-Liberal, Nicolás Isambert, A. Segado Soriano, Martin Wermke, Jennifer L. Cultrera, Ling Gao, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Charles S. Fuchs, Daniel P. Petrylak, Ian Chau
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lü, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Meili Sun, Liang Han, Liyun Miao, Cuimin Ding, Jiuwei Cui, Baolan Li, Yueyin Pan, Xingya Li, Feng Ye, Anwen Liu, Ke Wang, Shundong Cang, Hui Zhou, Xing Sun, David Ferry, Yong Lin, Shuyan Wang, Wen Zhang, Chengli Zhang